<!doctype html><html lang="zh-hans"><head><meta charset="utf-8"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title>免疫系统和COVID：仍然令人困惑 The immune system and COVID: It’s still confusing</title><link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/css/bootstrap.min.css" integrity="sha384-ggOyR0iXCbMQv3Xipma34MD+dH/1fQ784/j6cY/iJTQUOhcWr7x9JvoRxT2MZw1T" crossorigin="anonymous"><link rel="stylesheet" href="/img/css.css?random="><link data-rh="true" rel="icon" href="/img/favicon.ico"/><script data-ad-client="ca-pub-6067137220025946" async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script><script type="text/javascript" src="https://platform-api.sharethis.com/js/sharethis.js#property=5effb96910009800120b8d4d&product=inline-share-buttons" async="async"></script>
<script>var _hmt = _hmt || [];(function() {var hm = document.createElement("script");hm.src = "https://hm.baidu.com/hm.js?03c1a0f31299b4a2fbb83c34d6beaac9";var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s);})();</script></head><body><div id="my_header"><div class="container"><nav class="navbar navbar-expand-lg"><a class="navbar-brand" href="/"><img alt="diglog" src="/img/logo.v1.gif" class="rounded-sm"></a><button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarNavAltMarkup" aria-controls="navbarNavAltMarkup" aria-expanded="false" aria-label="Toggle navigation"><span class="navbar-toggler-icon"></span></button><div class="collapse navbar-collapse" id="navbarNavAltMarkup"><div class="navbar-nav"></div></div></nav></div></div><div class="container"><div id="my_content"><h1 class="page_narrow">The immune system and COVID: It’s still confusing<br/>免疫系统和COVID：仍然令人困惑 </h1><div class="row"><div class="col-lg-12 col-12"><div class="my_story_list_item shadow p-3 mb-5 bg-white rounded"><div class="story_page_pub_time page_narrow">2021-01-09 21:14:46</div><div class="story_img_container"><a href="http://img2.diglog.com/img/2021/1/ccd44a94384538dc90967f0423c436a7.jpg"><img src="http://img2.diglog.com/img/2021/1/ccd44a94384538dc90967f0423c436a7.jpg" class="img-fluid my_story_img" onerror="this.style.display='none'"></a></div><div class="page_narrow text-break page_content"><p>It&#39;s clear that the immune system can mount a robust response to SARS-CoV-2, as the vaccine trials have made clear. Beyond that, though, there are a lot of question marks. People exposed to the virus don&#39;t always produce much in the way of antibodies to it, and there have been a number of cases of reinfection. We&#39;re not sure how long immunity lasts or whether it correlates with antibody levels or something else–there hasn&#39;t even been great evidence that antibodies are helpful.</p><p>很明显，正如疫苗试验所表明的那样，免疫系统可以对SARS-CoV-2产生强大的反应。但是，除此之外，还有很多问号。接触该病毒的人通常不会以对其产生抗体的方式产生大量病毒，并且有许多重新感染的病例。我们不确定免疫能持续多长时间，或者它是否与抗体水平或其他因素有关-甚至没有证据表明抗体是有帮助的。</p><p> To give some sense of the challenge of sorting all of this out, we&#39;re going to look at three recently published papers that get at the interplay between the immune system and COVID-19. One finally provides some evidence that antibodies might be protective, another indicates that tamping down the inflammatory response might help, while the third suggests that immunosuppressives don&#39;t affect disease outcomes at all.</p><p> 为了对解决所有问题提出一些挑战，我们将看一下最近发表的三篇论文，探讨免疫系统和COVID-19之间的相互作用。最后，一个证据提供了抗体可能具有保护性的证据，另一个表明，抑制炎症反应可能有所帮助，而第三个证据表明，免疫抑制剂根本不会影响疾病的预后。</p><p>  Antibodies are a relatively easy way to track an immune response, and they&#39;ve been used for that throughout the pandemic. But early studies found the number of antibodies produced in response to an infection varied dramatically between patients. There have also been  clinical trials testing whether using antibodies obtained from those formerly infected could help treat those suffering from COVID-19 symptoms, with the FDA eventually  granting this a controversial Emergency Use Authorization. President Trump also received an experimental treatment of mass produced SARS-CoV-2-specific antibodies.</p><p>  抗体是追踪免疫反应的一种相对简单的方法，并且在整个大流行中都已使用它们。但早期研究发现，患者之间因感染而产生的抗体数量差异很大。还进行了一些临床试验，测试使用从以前感染者那里获得的抗体是否可以帮助治疗那些患有COVID-19症状的人，而FDA最终授予了这个有争议的紧急使用授权。特朗普总统还接受了大规模生产的SARS-CoV-2特异性抗体的实验治疗。</p><p> The odd thing about this is that we&#39;re not certain that antibodies are actually protective. Further trials of antibody treatments for those infected have produced ambiguous results, with no clear benefit from receiving an antibody boost. And while immunity levels seem to correlate with antibody levels in some studies, we can&#39;t be certain that the two aren&#39;t both linked to some other aspect of immune function—perhaps antibody levels are simply a reflection of T cell activity, to give one example.</p><p> 奇怪的是，我们不确定抗体实际上是否具有保护性。进一步针对受感染者进行抗体治疗的试验产生了模棱两可的结果，而接受抗体加强治疗并没有明显的益处。而且，尽管在某些研究中免疫力水平似乎与抗体水平相关，但我们不能确定两者都不与免疫功能的其他方面相关-也许抗体水平只是T细胞的反映活动，举一个例子。</p><p> A  new paper from researchers in Argentina is small, but it hints that antibodies can help those with COVID-19—but only if a treatment is administered early enough. The research design is solid: a randomized, blinded trial in which some people were given a transfusion of saline solution, while others had antibodies from those infected previously mixed in with their saline. Critically, all transfusions took place within a couple of days of the onset of COVID-19 symptoms. The only limitation of the trial is that it took place while case numbers were dropping in Argentina, so it was cut short once they had trouble recruiting patients.</p><p> 阿根廷研究人员发表的一篇新论文很小，但暗示抗体可以帮助COVID-19的患者，但前提是要尽早进行治疗。研究设计是可靠的：一项随机，盲法试验，其中一些人被输注了盐溶液，而另一些人则将先前被感染者的抗体与他们的盐混合。至关重要的是，所有输血都是在COVID-19症状发作后的几天内发生的。该试验的唯一局限性是发生在阿根廷的病例数下降的时候，因此一旦他们在招募患者方面遇到困难，就将其缩短。</p><p>    Of the 160 patients, all over 65 years of age, that were enrolled, 25 of the 80 in the control group ended up with severe respiratory symptoms. In those who received the antibody-containing plasma, only 13 experienced these symptoms. Eliminating the six individuals who had to drop out of the study improved the numbers further. Finally, those who received plasma with the highest levels of antibodies in it tended to have an even better prognosis, although the number of patients here is even smaller still.</p><p>    在所有年龄在65岁以上的160名患者中，对照组的80名患者中有25名最终出现了严重的呼吸道症状。在那些接受了含抗体血浆的人群中，只有13人经历了这些症状。剔除必须退出研究的六个人，进一步改善了人数。最后，尽管血浆中的患者人数仍然更少，但那些血浆中抗体水平最高的患者往往预后更好。</p><p> Those who received the plasma also tended to have fewer severe outcomes, such as admission to the ICU and need for ventilation. However, the numbers of each individual issue were all small, so none of these measures reached statistical significance.</p><p> 接受血浆治疗的人的严重后果也较少，例如入ICU和需要通气。但是，每个问题的数量都很少，因此这些措施均未达到统计意义。 </p><p> The researchers note that, in a few other studies, those who received plasma treatments early tended to do better, but the overall population treated at different stages of the infection showed no effect. If this turns out to be right—and this study is small enough that it really needs to be replicated—then it would present the first clear evidence that antibodies are helpful. That could be critical not only for the treatment of those who get infected, but in tracking immunity and monitoring risk in populations with various levels of vaccination.</p><p>研究人员指出，在其他一些研究中，早期接受血浆治疗的人往往表现更好，但是在感染的不同阶段接受治疗的总体人群没有效果。如果事实证明是正确的，并且这项研究足够小，以至于真的需要重复，那么它将提供第一个明确的证据证明抗体是有帮助的。这不仅对于感染者的治疗至关重要，而且对于追踪免疫力和监测接种不同水平疫苗的人群的风险也至关重要。</p><p>  The other lesson of the antibody study is that defining your treatment population carefully—newly symptomatic elderly, in this case—may be critical for identifying a clear effect, even though it can make it harder to find enough patients to do a thorough study. That lesson may also apply to  a draft manuscript that describes a study of whether we can limit the effects of COVID-19 by tamping down on the inflammatory immune response. Studies of the genetics of COVID-19 patients had indicated that variations in some immune signaling molecules were associated with disease severity. But studies of drugs that blocked the effects of an inflammatory signaling molecule called interleukin-6 had shown no effect. The researchers suspected that this was because they accepted a wide range of patients.</p><p>  抗体研究的另一个教训是，仔细确定您的治疗人群（在这种情况下，这是新症状的老年人）对于确定明确的效果可能至关重要，尽管这可能会很难找到足够的患者来进行彻底的研究。该课程可能还适用于描述有关是否可以通过降低炎症性免疫应答来限制COVID-19的作用的研究稿。对COVID-19患者的遗传学研究表明，某些免疫信号分子的变异与疾病的严重程度有关。但是，对阻断称为白细胞介素-6（炎性信号）的炎症信号分子的药物的研究没有显示任何作用。研究人员怀疑这是因为他们接受了广泛的患者。</p><p> So, to narrow things down, they started treatments with the interleukin-6 blockers as patients were admitted to the ICU. The trial enrolled about 800 people, about half of whom served as controls. The remainder received one of two different inflammatory blockers. Among those who didn&#39;t receive a drug, the mortality rate was about 36 percent. For those who were treated, however, mortality was 27 percent.</p><p> 因此，为了缩小范围，他们在患者进入ICU时开始使用IL-6受体阻滞剂进行治疗。该试验招募了约800人，其中约有一半为对照组。其余接受两种不同的炎性阻断剂之一。在没有接受药物治疗的人中，死亡率约为36％。然而，对于那些接受治疗的人来说，死亡率为27％。</p><p> That may not be an enormous difference, but if it holds up, it could make a significant difference in survival at the population level. And the UK&#39;s National Health Service has already alerted its doctors of the results as it starts a re-evaluation of these drugs.</p><p> 那可能不是很大的差异，但是如果坚持下去，就可以在人口水平上显着改变生存率。英国国家卫生服务局（National Health Service）已开始对这些药物进行重新评估，因此已经将其结果告知其医生。</p><p>     All of this would seemingly place the immune system at the center of COVID-19 outcomes, which shouldn&#39;t be in the least bit surprising. But another  study published this week raises questions about even that. Here, researchers tracked the outcomes of over 2,000 COVID-19 cases that came through the Johns Hopkins medical system back in March. Of those, over 100 were taking drugs that left them immunocompromised. And when the outcomes of the patients were analyzed, there wasn&#39;t a noticeable difference between those who were immunocompromised and the rest of the population. The researchers measured mortality, length of stay, and need for ventilation, but none of them were significantly different.</p><p>     所有这些似乎都将免疫系统置于COVID-19结果的中心，这一点一点也不令人惊讶。但是本周发表的另一项研究对此提出了疑问。在这里，研究人员追踪了3月份通过Johns Hopkins医疗系统传出的2,000多例COVID-19病例的结果。其中，有100多种正在服用使他们免疫受损的药物。并且在分析患者的结局时，免疫功能低下的人群与其余人群之间没有显着差异。研究人员测量了死亡率，住院时间和通风需求，但没有一个有显着差异。</p><p> It&#39;s important to emphasize that &#34;immunosuppressed&#34; does not mean &#34;incapable of mounting any immune response.&#34; But the response is generally quite limited.</p><p> 重要的是要强调免疫抑制。并不意味着不能进行任何免疫反应。但是反应通常很有限。</p><p> What to make of all of this? The good news is that, if the antibody results hold up, they indicate that antibodies can provide us not only with a therapy for those at high risk of severe infection, but an easy way of tracking who might be protected in the future. Those results aren&#39;t really confused by the results with immunocompromised individuals, since antibodies aren&#39;t typically produced during an initial infection unless it drags on for a while (they take a few weeks to start appearing at measurable levels).</p><p> 这一切怎么办？好消息是，如果抗体结果持续存在，它们表明抗体不仅可以为我们提供针对严重感染风险高的人群的疗法，而且可以为跟踪将来可能受到保护的人群提供一种简便方法。这些结果并不会与免疫功能低下的人的结果混淆，因为抗体通常不会在初次感染时产生，除非持续一段时间（它们需要花费几周才能开始以可测量的水平出现）。 </p><p> Beyond that, however, things get very complicated. The immune system has multiple aspects (T cell based immunity, dendritic cells, innate immunity, etc.), and we don&#39;t really know how many of these were fully suppressed in the immunocompromised individuals. In addition, if inflammation does turn out to be harmful in some cases, it&#39;s possible that some forms of immunosuppression could actually be helpful.</p><p>除此之外，事情变得非常复杂。免疫系统具有多个方面（基于T细胞的免疫，树突状细胞，先天性免疫等），我们真的不知道在免疫受损的个体中有多少个被完全抑制。另外，如果发炎确实在某些情况下有害，则某些形式的免疫抑制实际上可能会有所帮助。</p><p> But the big picture that these papers really drive home is that both the immune system and its interactions with this virus are extremely complex. If a study doesn&#39;t have enough people to focus on specific patient populations, or provide treatments at specific points during the infection, then there&#39;s a chance that important effects will be averaged out. One problem is that, at this point, we&#39;ve got many smaller, less focused studies already published, leading to an incomplete and confused picture. Finally, there&#39;s undoubtedly a lot of patient-to-patient variability that confuses things further.</p><p> 但是，这些论文真正带回家的大局是，免疫系统及其与这种病毒的相互作用都非常复杂。如果一项研究的人员不足，无法专注于特定的患者人群，或者在感染过程中的特定时间点不能提供治疗，那么很可能会平均得出重要的影响。一个问题是，在这一点上，我们已经发表了许多较小的，关注较少的研究，导致了不完整和混乱的情况。最后，毫无疑问，患者之间的差异很大，这进一步混淆了事情。</p><p> All of that explains why there&#39;s so many confusing and seemingly contradictory publications out there. It reinforces the need to treat any single result as conclusive. Over time, we will build up a clearer picture of the course of a SARS-CoV-2 infection and the immune system&#39;s response to it. Given the time that will take, however, the focus will undoubtedly be on rushing to get as many people vaccinated as quickly as possible.</p><p> 所有这些都解释了为什么那里有这么多令人困惑和看似矛盾的出版物。它强调需要将任何单个结果都视为结论性的。随着时间的流逝，我们将更加清晰地了解SARS-CoV-2感染的过程以及免疫系统对其的反应。但是，考虑到将要花费的时间，毫无疑问，重点将放在着急让尽可能多的人尽快接种疫苗。 </p></div><div id="story_share_this"><div class="sharethis-inline-share-buttons"></div></div><div class="text-break sotry_link page_narrow"><a target="_blank" href="https://arstechnica.com/science/2021/01/the-immune-system-and-covid-its-still-confusing/">https://arstechnica.com/science/2021/01/the-immune-system-and-covid-its-still-confusing/</a></div><div class="story_tags page_narrow"><button type="button" class="btn btn-light my_tag"><a href="/tag/免疫系统/">#免疫系统</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/system/">#system</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/抗体/">#抗体</a></button></div></div><div class="my_movie_list_item shadow p-3 mb-5 bg-white rounded"><button type="button" class="btn btn-link my_tag"><a href="/tag/web2.0/">#web2.0</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/google/">#google</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/设计/">#设计</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/创意/">#创意</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/摄影/">#摄影</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/图片/">#图片</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/游戏/">#游戏</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/软件/">#软件</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/视频/">#视频</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/手机/">#手机</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/广告/">#广告</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/iphone/">#iphone</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/网站/">#网站</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/免费/">#免费</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/下载/">#下载</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/windows/">#windows</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/微软/">#微软</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/苹果/">#苹果</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/apple/">#apple</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/firefox/">#firefox</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/blog/">#blog</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/音乐/">#音乐</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/博客/">#博客</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/wordpress/">#wordpress</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/恶搞/">#恶搞</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/qq/">#qq</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/艺术/">#艺术</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/web/">#web</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/工具/">#工具</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/分享/">#分享</a></button></div></div></div><div id="my_footer"><div class=""><a href="/tags/">tags</a> <a href="/users/">users</a></div>&copy; 2020 diglog.com </div></div></body></html>